TTY Biopharm Company Limited (TPEX:4105)
Taiwan
· Delayed Price · Currency is TWD 73.90
-0.60 (-0.81%)
Apr 24, 2025, 1:30 PM CST
TTY Biopharm Company Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 5,894 | 5,506 | 5,062 | 4,536 | 4,222 | Upgrade
|
| Revenue Growth (YoY) | 7.05% | 8.77% | 11.60% | 7.43% | -5.47% | Upgrade
|
| Cost of Revenue | 2,479 | 2,218 | 2,040 | 1,768 | 1,617 | Upgrade
|
| Gross Profit | 3,415 | 3,287 | 3,021 | 2,768 | 2,605 | Upgrade
|
| Selling, General & Admin | 1,750 | 1,601 | 1,436 | 1,325 | 1,388 | Upgrade
|
| Research & Development | 271.39 | 310.44 | 353.44 | 287.6 | 261.6 | Upgrade
|
| Other Operating Expenses | -1.44 | 4.95 | 0.38 | 1.43 | -2.28 | Upgrade
|
| Operating Expenses | 2,021 | 1,915 | 1,794 | 1,627 | 1,647 | Upgrade
|
| Operating Income | 1,394 | 1,372 | 1,228 | 1,141 | 957.38 | Upgrade
|
| Interest Expense | -38.26 | -35.18 | -22.85 | -18.97 | -19.41 | Upgrade
|
| Interest & Investment Income | 92.29 | 86.66 | 37.55 | 12.67 | 21.4 | Upgrade
|
| Earnings From Equity Investments | 400.05 | 131.34 | 116.38 | 135.18 | 162.87 | Upgrade
|
| Currency Exchange Gain (Loss) | 24.97 | 0.77 | 23.81 | 1.12 | -15.25 | Upgrade
|
| Other Non Operating Income (Expenses) | 20.53 | 17.29 | 29.5 | -178.39 | 101.01 | Upgrade
|
| EBT Excluding Unusual Items | 1,893 | 1,573 | 1,412 | 1,092 | 1,208 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | -35.74 | - | - | -1.56 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.95 | -1.93 | -3.28 | -0.74 | -0.32 | Upgrade
|
| Asset Writedown | -6.8 | -116.18 | -0.73 | -4.15 | -4.58 | Upgrade
|
| Pretax Income | 1,886 | 1,419 | 1,408 | 1,087 | 1,202 | Upgrade
|
| Income Tax Expense | 366.33 | 300.86 | 305.25 | 264.81 | 222.85 | Upgrade
|
| Earnings From Continuing Operations | 1,519 | 1,119 | 1,103 | 822.57 | 978.68 | Upgrade
|
| Minority Interest in Earnings | -69.73 | 9.91 | -8.7 | 9.33 | -54.5 | Upgrade
|
| Net Income | 1,450 | 1,129 | 1,094 | 831.89 | 924.18 | Upgrade
|
| Net Income to Common | 1,450 | 1,129 | 1,094 | 831.89 | 924.18 | Upgrade
|
| Net Income Growth | 28.46% | 3.12% | 31.55% | -9.99% | 2.68% | Upgrade
|
| Shares Outstanding (Basic) | 249 | 249 | 249 | 249 | 249 | Upgrade
|
| Shares Outstanding (Diluted) | 249 | 249 | 249 | 249 | 249 | Upgrade
|
| Shares Change (YoY) | 0.04% | 0.03% | -0.02% | -0.00% | 0.03% | Upgrade
|
| EPS (Basic) | 5.83 | 4.54 | 4.40 | 3.35 | 3.72 | Upgrade
|
| EPS (Diluted) | 5.82 | 4.53 | 4.40 | 3.34 | 3.71 | Upgrade
|
| EPS Growth | 28.48% | 2.96% | 31.74% | -9.97% | 2.77% | Upgrade
|
| Free Cash Flow | 1,224 | 1,007 | 1,144 | 1,196 | 358.25 | Upgrade
|
| Free Cash Flow Per Share | 4.91 | 4.04 | 4.59 | 4.80 | 1.44 | Upgrade
|
| Dividend Per Share | 4.200 | 3.500 | 3.400 | 3.000 | 4.000 | Upgrade
|
| Dividend Growth | 20.00% | 2.94% | 13.33% | -25.00% | - | Upgrade
|
| Gross Margin | 57.94% | 59.70% | 59.69% | 61.03% | 61.70% | Upgrade
|
| Operating Margin | 23.65% | 24.93% | 24.26% | 25.15% | 22.68% | Upgrade
|
| Profit Margin | 24.60% | 20.50% | 21.62% | 18.34% | 21.89% | Upgrade
|
| Free Cash Flow Margin | 20.77% | 18.29% | 22.61% | 26.37% | 8.49% | Upgrade
|
| EBITDA | 1,588 | 1,566 | 1,409 | 1,303 | 1,111 | Upgrade
|
| EBITDA Margin | 26.95% | 28.43% | 27.83% | 28.74% | 26.32% | Upgrade
|
| D&A For EBITDA | 194.26 | 193.1 | 180.69 | 162.79 | 153.86 | Upgrade
|
| EBIT | 1,394 | 1,372 | 1,228 | 1,141 | 957.38 | Upgrade
|
| EBIT Margin | 23.65% | 24.93% | 24.26% | 25.15% | 22.68% | Upgrade
|
| Effective Tax Rate | 19.43% | 21.20% | 21.67% | 24.35% | 18.55% | Upgrade
|
Updated Feb 26, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.